Cat. No. 3577
Chemical Name: (±)-1-[(3aR*,4S*,9bS*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]- ethanone
Biological ActivityPotent and selective GPR30 receptor agonist (Ki = 11 nM, EC50 = 2 nM); displays no activity at ERα and ERβ at concentrations up to 10 μM. Increases cytosolic Ca2+ and inhibits migration of SKBr3 cells and MCF-7 cells in response to chemoattractants (IC50 values are 0.7 and 1.6 nM respectively) in vitro. Blocks MCF-1 cell cycle progression at the G1 phase. Displays therapeutic effects in the mouse EAE model of multiple sclerosis.
Licensing InformationNot for sale in the USA.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Bologa et al (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nature Chem.Biol. 2 207.
Albanito et al (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 67 1859. PMID: 17308128.
Blasko et al (2009) Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J.Neuroimmunol. 214 67. PMID: 19664827.
Ariazi et al (2010) The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 70 1184. PMID: 20086172.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: G-1, supplier, Potent, selective, G1, GPR30, agonists, receptors, estrogen, oestrogen, G, protein-coupled, receptor, 30
Find multiple products by catalog number
New Products in this Area
Potent and selective S1P4 agonistH2L5186303
Potent and selective LPA2 receptor antagonistMEDICA 16
FFA1 (GPR40) agonist. Also inhibits ATP citrate lyaseBX 471
Potent, selective CCR1 antagonistPF 04418948
Potent and selective EP2 receptor antagonistLatanoprost
FP prostaglandin receptor agonist; also exhibits agonist activity at EP1 and EP3 receptorsGRI 977143
Selective LPA2 receptor non-lipid agonistCYM 50260
Potent and selective S1P4 agonistG-36
Selective GPR30 antagonistStrontium chloride
Calcium sensing receptor (CaSR) agonistCS 2100
Selective S1P1 agonistSMANT hydrochloride
Inhibits Smoothened (Smo) accumulationTUG 891
Potent and selective GPR120 agonistIT1t dihydrochloride
Potent CXCR4 antagonistRuBi GABA trimethylphosphine
Caged GABA; inhibits neural activity
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.